Tumour-infiltrating lymphocytes (TILs) in breast cancer: A predictive or a prognostic marker?

被引：3
作者：
Dushyanthen S. [1 ]
Savas P. [1 ]
Willard-Gallo K. [2 ]
Denkert C. [3 ,4 ]
Salgado R. [5 ]
Loi S. [1 ]
机构：
[1] Division of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC
[2] Institute Jules Bordet, Brussels
[3] Institute of Pathology, Charité University Hospital, Berlin
[4] German Cancer Consortium (DKTK), Berlin
[5] Breast Cancer Translational Research Laboratory/Breast International Group, Institute Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp
来源：
Current Breast Cancer Reports | 2015年 / 7卷 / 1期
关键词：
Breast cancer; Immunity generation; Immunity suppression; TILs; Tumour-infiltrating lymphocytes;
D O I：
10.1007/s12609-014-0178-4
中图分类号：
学科分类号：
摘要：
Breast cancer has not been considered as an immunogenic solid cancer type; however, recent studies demonstrate evidence of significant prognostic information that can be derived from immune cell infiltration via tumour-infiltrating lymphocytes (TILs) in patient tumours. The presence of TILs has been associated with increased response rates to cytotoxic chemotherapy as well as targeted therapies, leading to improved disease-free and overall survival in certain breast cancer subtypes. Accordingly, experts have developed a standardized methodology for evaluating TILs within clinical specimens in histopathological practice. An overview of a newly established practical guideline for TIL evaluation in breast cancer is described in this paper. Furthermore, this review discusses the predictive and prognostic significance of TILs, highlighting recent evidence linking TILs to prognosis in breast cancer. In addition, it summarizes the most current understanding of TIL composition as well as mechanisms of immunity generation and suppression. Overall, the current literature demonstrates that TILs are proving to be a promising target for the treatment of immunogenic breast cancers. © Springer Science+Business Media New York 2015.
引用
收藏
页码：59 / 70
页数：11
相关论文
共 95 条
[1]  
Liu S., Et al., CD8<sup>+</sup> lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer, Breast Cancer Res, 14, 2, (2012)
[2]  
Ono M., Et al., Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer, Breast Cancer Res Treat, 132, 3, pp. 793-805, (2012)
[3]  
West N.R., Et al., Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer, Br J Cancer, 108, 1, pp. 155-162, (2013)
[4]  
Yamaguchi R., Et al., Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer, Hum Pathol, 43, 10, pp. 1688-1694, (2012)
[5]  
Sun S., Et al., PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients, Cancer Immunol Immunother, 63, 4, pp. 395-406, (2014)
[6]  
Adams S., Et al., Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199, J Clin Oncol, 32, 27, pp. 2959-2966, (2014)
[7]  
Loi S., Et al., Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial, Ann Oncol, 25, 8, pp. 1544-1550, (2014)
[8]  
Ali H.R., Et al., Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann Oncol, 25, 8, pp. 1536-1543, (2014)
[9]  
Denkert C., Et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 1, pp. 105-113, (2010)
[10]  
Issa-Nummer Y., Et al., Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial, PLoS One, 8, 12, (2013)
12345678910